Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia.
Emily HuschartHolly MillerDana SalzbergCourtney CampbellKristen BeebeCharlotte SchwalbachKyrie MageeRoberta H AdamsAlexander NgwubePublished in: Pediatric hematology and oncology (2020)
Post-hematopoietic stem cell transplantation (HSCT) maintenance therapy using azacitidine and prophylactic donor lymphocyte infusions (DLI) was implemented for high-risk acute myeloid leukemia. Azacitidine was started on day +60 as a 5 day course every 28 days for 6 cycles. DLI was given every 6 weeks for 3 doses starting after day +120. Ten patients were treated on this protocol. With a 90% one-year disease free survival, we report this post-HSCT maintenance therapy is feasible, safe, and well tolerated.
Keyphrases
- acute myeloid leukemia
- free survival
- allogeneic hematopoietic stem cell transplantation
- newly diagnosed
- end stage renal disease
- ejection fraction
- chronic kidney disease
- peripheral blood
- randomized controlled trial
- prognostic factors
- hematopoietic stem cell
- patient reported outcomes
- acute lymphoblastic leukemia
- patient reported
- young adults
- gestational age
- childhood cancer